BITESIZE: New Study: Why Did This Drug Lower Cholesterol But Not Heart Plaque?
About this episode
Dr. Bret Scher discusses a new study on Olezarsen and its implications for treating cardiovascular disease.
Lower triglycerides, lower remnant cholesterol, lower ApoB. Zero change in coronary artery plaque. A new clinical trial is forcing a bigger conversation about how we treat cardiovascular disease. The drug was Olezarsen, an APOC3 inhibitor. The blood work looked impressive. The heart scans did not. So why would lowering well-established cardiovascular risk factors fail to move the needle on plaque? Dr. Bret Scher argues there's a critical difference between what we want to fix and how we go about fixing it. Lowering a number with a drug is not the same as addressing the underlying metabolic dysfunction that caused that number to be high in the first place. In this video, you'll learn: What the Olezarsen trial actually showed and why the results matter Why elevated triglycerides often signal deeper metabolic dysfunction and insulin resistance How this same drug-first thinking plays out in type 2 diabetes, hypertension, and weight management Why narrowing our focus to "fix the number" can keep us from healing the whole system How metabolic medicine reframes the conversation around root causes This isn't an argument against medication. Responsible drug use has an important place in…
More episodes of Metabolic Mind
- Keto as an Adjunct to CBTp? Nicole Laurent Explains
- Q&A: Keto for PCOS, Cravings, & Women’s Health with Temple Stewart
- GLP-1s, Weight Loss, and the Stigma We Don’t Talk About
- APA Hallway Talk: Are Psych Meds Overprescribed?
- Eggs and Alzheimer’s: New Study Challenges Assumptions
- Reversing & Preventing Fatty Liver with Metabolic Therapies | Dr. Adam Wolfberg
Explore listener stats, chart rankings, contacts and more on the Metabolic Mind podcast page.